Literature DB >> 8001596

Inter- and intra-subject variability of metoprolol kinetics after intravenous administration.

J Richard1, J M Cardot, J Godbillon.   

Abstract

The pharmacokinetics of metoprolol were assessed from the data of 3 experiments in which intravenous deuterated metoprolol was given concomitantly with various oral metoprolol formulations to healthy volunteers. The plasma levels after intravenous administration were well described by a biexponential equation. However, a deviation from a pure biphasic decline was observed over a short period of time, immediately after the rapid elimination phase. The inter- and intra-subject variability of the parameters describing the two-compartment model was large. The intra-subject variability of the terminal half-life and the plasma clearance was lower than their inter-subject variability. The plasma clearance was linearly related to 1/t1/2. Contrarily to the other parameters of the model, t1/2 appeared to be a characteristic of the subject.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8001596     DOI: 10.1007/BF03188836

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  10 in total

1.  Combined pharmacokinetic and pharmacodynammc studies in man of the adrenergic beta1-receptor antagonist metoprolol.

Authors:  G Johnsson; C G Regårdh; L Sölvell
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

2.  Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method.

Authors:  J M Strong; J S Dutcher; W K Lee; A J Atkinson
Journal:  Clin Pharmacol Ther       Date:  1975-11       Impact factor: 6.875

3.  The application of stable isotopes to studies of drug bioavailability and bioequivalence.

Authors:  R L Wolen
Journal:  J Clin Pharmacol       Date:  1986 Jul-Aug       Impact factor: 3.126

4.  Plasma concentrations and beta-blocking effects in normal volunteers after intravenous doses of metoprolol and propranolol.

Authors:  C G Regårdh; G Johnsson; L Jordö; P Lungborg; B A Persson; O Rönn
Journal:  J Cardiovasc Pharmacol       Date:  1980 Nov-Dec       Impact factor: 3.105

5.  Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.

Authors:  M S Lennard; J H Silas; S Freestone; J Trevethick
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

6.  Simultaneous determination of metoprolol and deuterium-labelled metoprolol in human plasma by gas chromatography-negative-ion mass spectrometry.

Authors:  D Gaudry; D Wantiez; J Richard; J P Metayer
Journal:  J Chromatogr       Date:  1985-05-03

7.  Mathematical basis of point-area deconvolution method for determining in vivo input functions.

Authors:  D P Vaughan; M Dennis
Journal:  J Pharm Sci       Date:  1978-05       Impact factor: 3.534

8.  Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man.

Authors:  C G Regårdh; K O Borg; R Johansson; G Johnsson; L Palmer
Journal:  J Pharmacokinet Biopharm       Date:  1974-08

9.  Pharmacokinetics of metoprolol in patients with hepatic cirrhosis.

Authors:  C G Regårdh; L Jordö; M Ervik; P Lundborg; R Olsson; O Rönn
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

10.  Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function.

Authors:  L Jordö; P O Attman; M Aurell; L Johansson; G Johnsson; C G Regårdh
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

  10 in total
  6 in total

1.  Bayesian analysis of population PK/PD models: general concepts and software.

Authors:  David J Lunn; Nicky Best; Andrew Thomas; Jon Wakefield; David Spiegelhalter
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-06       Impact factor: 2.745

2.  Non randomized study on the potential of nitisinone to inhibit cytochrome P450 2C9, 2D6, 2E1 and the organic anion transporters OAT1 and OAT3 in healthy volunteers.

Authors:  Gunilla Huledal; Birgitta Olsson; Kristin Önnestam; Per Dalén; Daniel Lindqvist; Matthias Kruse; Anders Bröijersén
Journal:  Eur J Clin Pharmacol       Date:  2018-11-15       Impact factor: 2.953

3.  Clinical Pharmacokinetics of Metoprolol: A Systematic Review.

Authors:  Ammara Zamir; Iltaf Hussain; Anees Ur Rehman; Waseem Ashraf; Imran Imran; Hamid Saeed; Abdul Majeed; Faleh Alqahtani; Muhammad Fawad Rasool
Journal:  Clin Pharmacokinet       Date:  2022-06-28       Impact factor: 5.577

4.  Stable isotope methodology for studying the performance of metoprolol Oros tablets in comparison to conventional and slow release formulations.

Authors:  J Richard; J M Cardot; J Godbillon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Oct-Dec       Impact factor: 2.441

5.  Are Physiologically Based Pharmacokinetic Models Reporting the Right C(max)? Central Venous Versus Peripheral Sampling Site.

Authors:  Helen Musther; Katherine L Gill; Manoranjenni Chetty; Amin Rostami-Hodjegan; Malcolm Rowland; Masoud Jamei
Journal:  AAPS J       Date:  2015-06-23       Impact factor: 4.009

6.  Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum
Journal:  Crit Care       Date:  2021-06-10       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.